FDA grants Kitov waiver for new drug application filing fee
European Pharmaceutical Review | April 06, 2017
The US Food and Drug Administration (FDA) has granted Kitov Pharmaceuticals a waiver related to the $2,038,100 new drug application filing fee for KIT-302.